J&J advances IBD combo to Phase 3 despite Phase 2 setbacks
Johnson & Johnson said it will advance its experimental inflammatory bowel disease therapy, JNJ-4804, into Phase 3 trials even though the drug failed to meet primary endpoints in two Phase 2 studies. The combination includes the approved biologic Tremfya and an additional agent, but the company believes the data still justify larger testing.
The Phase 2 results showed no statistically significant improvement over placebo, prompting analysts to question the regimen’s efficacy. J&J highlighted safety signals and subgroup trends as reasons to proceed.
The move signals J&J’s commitment to expanding its IBD pipeline, and the upcoming pivotal trial will be closely watched by investors and clinicians seeking new treatment options.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that